mug134 Antibody

What is the mug134 Antibody and what organism does it target?

The mug134 Antibody (product code CSB-PA520368XA01SXV) is a polyclonal antibody raised in rabbits against recombinant Schizosaccharomyces pombe (strain 972 / ATCC 24843), commonly known as fission yeast. This antibody specifically targets the mug134 protein, which has the UniProt accession number O42654. The antibody is generated through immunization with a recombinant form of the target protein and is subsequently purified using antigen affinity methods to ensure specificity .

For optimal results when working with this antibody, researchers should consider the evolutionary conservation of the target protein across species and validate cross-reactivity if applying it to organisms other than S. pombe. When designing experiments, it's important to note that while the antibody is raised against the specific strain mentioned, epitope conservation may allow detection of homologous proteins in related yeast strains, though this requires experimental validation.

What are the recommended storage conditions for mug134 Antibody?

The mug134 Antibody should be stored at either -20°C or -80°C immediately upon receipt. It's crucial to avoid repeated freeze-thaw cycles as they can lead to protein denaturation and loss of antibody activity . For practical laboratory management, the following methodological approach is recommended:

• Upon receipt, aliquot the antibody into single-use volumes based on your typical experimental needs.

• Use sterile microcentrifuge tubes for aliquoting.

• Clearly label each aliquot with the antibody name, date of aliquoting, and any dilution information.

• When removing from storage, thaw only the required aliquot(s) on ice.

• Return unused aliquots to -20°C or -80°C immediately.

This aliquoting strategy preserves antibody integrity by preventing protein degradation that occurs during repeated temperature fluctuations. For long-term storage exceeding 6 months, -80°C is preferable to -20°C to minimize gradual activity loss.

What applications has the mug134 Antibody been validated for?

The mug134 Antibody has been validated for Enzyme-Linked Immunosorbent Assay (ELISA) and Western Blot (WB) applications . When implementing these methods, researchers should consider the following methodological approaches:

For ELISA applications:

• Use a starting antibody dilution range of 1:1000 to 1:5000.

• Optimize blocking conditions (typically 5% non-fat milk or BSA in PBST).

• Include appropriate positive and negative controls.

• Consider indirect ELISA format, with the antigen immobilized on the plate surface.

For Western Blot applications:

• Begin with protein separation on SDS-PAGE gels (10-12% typically suitable).

• Transfer proteins to PVDF or nitrocellulose membranes.

• Block with 5% blocking agent in TBST.

• Incubate with primary antibody (starting dilution 1:1000).

• Detect using appropriate secondary antibody (anti-rabbit HRP conjugate).

• Develop using chemiluminescence or other compatible detection methods.

For each application, optimization of antibody concentration, incubation times, and buffer conditions is essential for obtaining specific signals while minimizing background.

What is the composition of the storage buffer for mug134 Antibody?

The mug134 Antibody is supplied in a liquid form with a storage buffer composed of 0.03% Proclin 300 (preservative), 50% Glycerol, and 0.01M PBS at pH 7.4 . This formulation serves multiple purposes:

• The 50% glycerol acts as a cryoprotectant, preventing freezing damage at -20°C storage.

• Proclin 300 at 0.03% inhibits microbial growth without interfering with antibody activity.

• The PBS at pH 7.4 maintains physiological pH and ionic strength.

When designing experiments, researchers should consider potential buffer interference with specific applications. For instance, high glycerol content may affect protein quantification methods and loading into gel wells for electrophoresis. In such cases, diluting the antibody in application-specific buffers prior to use is recommended. For applications sensitive to preservatives, researchers may need to dialyze the antibody against a preservative-free buffer, though this will reduce shelf life and may require stricter aseptic handling.

How can specificity of mug134 Antibody be validated in experimental systems?

Validating antibody specificity is crucial for ensuring experimental integrity. For mug134 Antibody, which targets a Schizosaccharomyces pombe protein, consider these methodological approaches:

• Genetic validation: Use mug134 knockout/knockdown strains as negative controls alongside wild-type S. pombe.

• Peptide competition assay: Pre-incubate the antibody with excess purified mug134 peptide before application to samples. Signal reduction indicates specificity.

• Orthogonal detection methods: Compare results with alternative antibodies targeting different epitopes of the same protein.

• Mass spectrometry validation: Immunoprecipitate with the antibody and confirm target identity by mass spectrometry.

A comprehensive validation protocol similar to what was employed for the monoclonal antibody MS13 against plasmatocytes would involve:

• Western blot analysis to confirm molecular weight (expected to be approximately the predicted molecular weight of mug134 protein)

• Immunohistochemistry with appropriate controls

• Functional inhibition assays if applicable

Document all validation experiments with appropriate controls in a systematic manner to establish confidence in antibody specificity before proceeding with complex experimental designs.

How can researchers optimize epitope retrieval when using mug134 Antibody for fixed samples?

Although not explicitly mentioned in the product information, epitope retrieval optimization is critical when working with fixed samples. For mug134 Antibody against a yeast protein, consider the following methodological approach:

• Compare multiple fixation methods in parallel:

  • 4% paraformaldehyde (10-20 minutes)

  • 70-95% ethanol (30 minutes)

  • Methanol (-20°C, 5-10 minutes)

• For each fixation method, test different epitope retrieval techniques:

  • Heat-induced epitope retrieval using citrate buffer (pH 6.0) or Tris-EDTA (pH 9.0)

  • Enzymatic retrieval using proteinase K (1-5 μg/ml, 5-15 minutes)

  • No retrieval (control)

• Systematically document signal intensity and background for each condition using a standardized scoring system.

For yeast cell preparations, additional considerations include cell wall digestion with zymolyase or lyticase prior to immunostaining, which may significantly improve antibody accessibility to intracellular epitopes.

What approaches can be used to characterize the binding kinetics of mug134 Antibody?

Understanding the binding kinetics of mug134 Antibody provides critical information for experimental design and interpretation. Advanced biophysical methods can be employed:

• Surface Plasmon Resonance (SPR):

  • Immobilize purified recombinant mug134 protein on a sensor chip

  • Flow antibody at multiple concentrations over the surface

  • Analyze association (ka) and dissociation (kd) rate constants

  • Calculate equilibrium dissociation constant (KD = kd/ka)

• Bio-Layer Interferometry (BLI):

  • Immobilize antibody on biosensor tips

  • Expose to various concentrations of antigen

  • Measure real-time binding kinetics

  • Determine on/off rates and affinity constants

• Isothermal Titration Calorimetry (ITC):

  • Directly measure thermodynamic parameters of binding

  • Obtain KD, stoichiometry, enthalpy (ΔH), and entropy (ΔS)

Similar to approaches used in antibody specificity research , these methods provide quantitative data on binding characteristics that can inform experimental design decisions such as incubation times, washing stringency, and antibody concentrations.

How can mug134 Antibody be adapted for multiplex immunoassays?

Adapting mug134 Antibody for multiplex analysis requires careful consideration of potential cross-reactivity and detection strategies. A methodological approach includes:

• Conjugation strategies:

  • Direct labeling with fluorophores (Alexa Fluor dyes, FITC, etc.)

  • Biotinylation for subsequent detection with streptavidin-conjugated reporters

  • Coupling to distinct quantum dots for spectral multiplexing

• Validation of conjugated antibody:

  • Compare activity pre- and post-conjugation

  • Titrate to determine optimal working concentration

  • Assess cross-reactivity with other antibodies in the multiplex panel

• Multiplex assay development:

  • For flow cytometry: Use compensation controls to correct spectral overlap

  • For imaging: Employ sequential staining if cross-reactivity is observed

  • For bead-based assays: Assign unique bead identifiers for the mug134 target

Similar to the approach used in systems serology , developing a quantitative framework for analyzing multiplex data from different antibody classes can provide insights into complex biological systems. When designing multiplex panels, it's essential to consider the species origin of all antibodies to avoid secondary antibody cross-reactivity.

What controls should be included when using mug134 Antibody in experimental protocols?

Proper controls are essential for meaningful interpretation of results when using mug134 Antibody. A comprehensive control strategy includes:

• Primary controls:

  • Positive control: Confirmed mug134-expressing S. pombe samples

  • Negative control: mug134 knockout/knockdown S. pombe strains

  • Isotype control: Non-specific rabbit IgG at matching concentration

• Technical controls:

  • Secondary antibody only (omit primary antibody)

  • Antigen pre-absorption control (antibody pre-incubated with excess target)

  • Gradient of antigen concentrations for calibration

• Cross-reactivity controls:

  • Related yeast species to assess specificity

  • When studying potential homologs in other organisms, include species-specific negative controls

For quantitative applications, include a standard curve using recombinant mug134 protein at known concentrations. For immunohistochemistry or immunocytochemistry, include tissue/cells known not to express the target protein as negative controls.

The importance of proper controls is demonstrated in antibody validation studies where rigorous control frameworks helped distinguish specific from non-specific binding .

What is the recommended protocol for using mug134 Antibody in Western blotting?

For optimal Western blot results with mug134 Antibody, the following detailed protocol is recommended:

• Sample preparation:

  • Lyse S. pombe cells in RIPA buffer supplemented with protease inhibitors

  • Clarify lysate by centrifugation (14,000 × g, 15 min, 4°C)

  • Quantify protein concentration using Bradford or BCA assay

• SDS-PAGE:

  • Prepare 10-12% polyacrylamide gels

  • Load 20-40 μg protein per lane

  • Include molecular weight markers

• Transfer:

  • Transfer to PVDF membrane (0.45 μm pore size)

  • Use semi-dry or wet transfer systems (25V for 1.5 hours)

  • Verify transfer with Ponceau S staining

• Immunoblotting:

  • Block membrane with 5% non-fat milk in TBST (1 hour, room temperature)

  • Incubate with mug134 Antibody at 1:1000 dilution in blocking buffer (overnight, 4°C)

  • Wash 3× with TBST (10 min each)

  • Incubate with HRP-conjugated anti-rabbit secondary antibody (1:5000, 1 hour, room temperature)

  • Wash 3× with TBST (10 min each)

  • Develop using ECL substrate and detect using appropriate imaging system

• Analysis:

  • Quantify band intensity using image analysis software

  • Normalize to loading control (e.g., β-actin)

Key optimization steps may include adjusting antibody dilution, incubation time, and blocking agent. For particularly challenging samples, signal enhancement systems or more sensitive detection reagents may be necessary.

How should mug134 Antibody be validated for cross-reactivity with homologous proteins?

Validating cross-reactivity of mug134 Antibody with homologous proteins requires a systematic approach:

• Bioinformatic analysis:

  • Identify potential homologs across species using BLAST or similar tools

  • Align sequences to identify conserved epitope regions

  • Predict potential cross-reactivity based on sequence similarity

• Recombinant protein validation:

  • Express and purify homologous proteins from related species

  • Test antibody binding using ELISA or Western blot

  • Quantify relative binding affinity compared to the original target

• Cellular/tissue validation:

  • Test antibody against samples from various species

  • Compare staining patterns with known expression profiles

  • Use genetic knockouts/knockdowns as controls when available

• Epitope mapping:

  • Generate peptide arrays covering the target protein sequence

  • Identify the specific binding region of mug134 Antibody

  • Compare epitope conservation across homologs

This methodological approach resembles strategies used in antibody specificity research where computational models helped predict cross-reactivity patterns. Document results in a systematic format:

What strategies can optimize immunoprecipitation using mug134 Antibody?

Optimizing immunoprecipitation (IP) with mug134 Antibody involves several key considerations:

• Antibody coupling:

  • Direct coupling to activated beads (e.g., CNBr-activated Sepharose)

  • Use of Protein A/G beads for indirect capture

  • Orientation-specific coupling via Fc region to maximize antigen accessibility

• Buffer optimization:

  • Test multiple lysis buffers (RIPA, NP-40, Triton X-100)

  • Adjust salt concentration (150-500 mM NaCl)

  • Include protease inhibitors and phosphatase inhibitors if studying post-translational modifications

• IP protocol optimization:

  • Pre-clearing lysate with beads alone

  • Antibody concentration titration (1-10 μg per mg total protein)

  • Incubation time and temperature variations (2 hours to overnight, 4°C)

  • Washing stringency optimization

• Elution strategies:

  • Gentle: Low pH glycine buffer (pH 2.8)

  • Denaturing: SDS sample buffer with heating

  • For mass spectrometry: Peptide competition or on-bead digestion

Similar to approaches used in investigating antibody-mediated immune functions , systematic optimization of each parameter while holding others constant can identify optimal conditions. Document the effectiveness of different conditions by measuring the ratio of target protein to non-specific background proteins in the eluate.

How should quantitative data from mug134 Antibody experiments be normalized?

Proper normalization of quantitative data is crucial for meaningful interpretation of results from mug134 Antibody experiments:

• Western blot normalization options:

  • Housekeeping proteins (e.g., β-actin, GAPDH, tubulin)

  • Total protein normalization using stain-free technology or Ponceau S

  • Loading control spike-ins of known concentration

• ELISA normalization approaches:

  • Standard curve using recombinant mug134 protein

  • Reference sample inclusion across all plates

  • Background subtraction from negative control wells

• Flow cytometry normalization:

  • Fluorescence minus one (FMO) controls

  • Median fluorescence intensity (MFI) normalization

  • Bead-based calibration to absolute molecules of equivalent soluble fluorochrome (MESF)

• Statistical considerations:

  • Test for normal distribution before applying parametric tests

  • Use appropriate transformations (log, square root) if needed

  • Account for batch effects using appropriate statistical models

This approach aligns with quantitative analysis methods used in antibody research , where systematic normalization enables detection of subtle biological differences. For time-course experiments or comparisons across multiple conditions, consider using relative normalization to a selected reference condition.

How can researchers distinguish between specific and non-specific binding in mug134 Antibody applications?

Distinguishing specific from non-specific binding is essential for accurate data interpretation:

• Experimental approaches:

  • Competitive inhibition with excess soluble antigen

  • Comparison with isotype control antibody

  • Concentration-dependent binding analysis (saturation curve)

  • Signal persistence after stringent washing conditions

• Analytical methods:

  • Signal-to-noise ratio quantification

  • Comparison of binding patterns to known expression profiles

  • Co-localization with orthogonal detection methods

  • Statistical analysis of replicate measurements

• Advanced techniques:

  • Super-resolution microscopy to analyze spatial distribution

  • FRET-based proximity analysis for co-localization

  • Single-molecule imaging to assess binding kinetics

Similar to the approach used in evaluating antibody specificity in complex systems , computational analysis of binding patterns across multiple conditions can help distinguish specific from non-specific interactions. For complex samples, consider using machine learning algorithms trained on positive and negative controls to classify binding patterns.

What statistical approaches are recommended for analyzing variability in mug134 Antibody experimental results?

Proper statistical analysis is essential for robust interpretation of experimental variability:

• Descriptive statistics:

  • Central tendency measures (mean, median)

  • Dispersion measures (standard deviation, interquartile range)

  • Visualization using box plots, violin plots, or scatter plots

• Inferential statistics:

  • Parametric tests (t-test, ANOVA) for normally distributed data

  • Non-parametric alternatives (Mann-Whitney U, Kruskal-Wallis) for non-normal data

  • Paired tests for before-after comparisons within samples

• Advanced statistical approaches:

  • Mixed-effects models for nested experimental designs

  • Bayesian analysis for incorporating prior knowledge

  • Bootstrap methods for robust confidence interval estimation

• Sample size and power considerations:

  • A priori power analysis to determine required sample size

  • Post hoc power analysis to interpret negative results

  • Effect size reporting alongside p-values

This methodological approach aligns with systems analysis techniques used in antibody research , where variability analysis helps identify underlying biological mechanisms. For multi-parameter experiments, consider dimensionality reduction techniques like principal component analysis (PCA) to identify major sources of variation.

What are common sources of background in mug134 Antibody applications and how can they be mitigated?

Background issues can significantly impact data quality. Here are methodological approaches to identify and address common sources:

• Non-specific antibody binding:

  • Increase blocking agent concentration (5-10% BSA or non-fat milk)

  • Add 0.1-0.5% Tween-20 to wash buffers

  • Include carrier proteins (0.1-1% BSA) in antibody dilution buffer

  • Titrate antibody to optimal concentration

• Cross-reactivity:

  • Pre-adsorb antibody against related proteins

  • Increase washing stringency (higher salt, more wash steps)

  • Use more selective detection methods

• Sample-specific interference:

  • For yeast samples, thoroughly remove cell wall components

  • Pre-clear lysates before immunoprecipitation

  • Use detergent-compatible blocking agents if sample contains lipids

• Detection system background:

  • Use freshly prepared substrates

  • Optimize exposure times/detector settings

  • Include system-specific blank controls

This troubleshooting approach is similar to methods used in developing specific antibody applications , where systematic optimization of multiple parameters led to improved signal-to-noise ratios. Document all optimization steps in a laboratory notebook for reproducibility.

How can researchers troubleshoot weak or absent signals when using mug134 Antibody?

When facing weak or absent signals, consider this systematic troubleshooting approach:

• Sample preparation issues:

  • Verify target protein expression in samples

  • Check protein extraction efficiency

  • Ensure protein integrity (minimize proteolysis)

  • Consider epitope accessibility (denaturation for Western blots, fixation impact for IHC)

• Antibody-related factors:

  • Verify antibody activity (test with positive control)

  • Increase antibody concentration

  • Extend incubation time (overnight at 4°C)

  • Check for potential interference from storage buffer

• Detection system optimization:

  • Use more sensitive detection reagents

  • Increase substrate incubation time

  • Employ signal amplification methods (e.g., tyramide signal amplification)

  • Check equipment settings and functionality

• Systematic optimization grid:

Similar to approaches used in optimizing antibody applications for specific contexts , this methodical testing of multiple parameters can identify optimal conditions. Document all results systematically to identify patterns that may indicate the source of the problem.

What approaches can optimize mug134 Antibody performance across different experimental platforms?

Optimizing antibody performance across diverse platforms requires platform-specific considerations:

• Western blot optimization:

  • Test different membrane types (PVDF vs. nitrocellulose)

  • Optimize transfer conditions for the target protein size

  • Evaluate blocking agents for minimal background

  • Consider enhanced chemiluminescence systems for sensitivity

• ELISA optimization:

  • Compare direct vs. indirect coating strategies

  • Test different plate types (standard vs. high-binding)

  • Optimize coating buffer composition and pH

  • Evaluate detection antibody options

• Immunofluorescence optimization:

  • Test different fixation methods

  • Optimize permeabilization conditions

  • Evaluate antigen retrieval methods

  • Test mounting media for signal preservation

• Flow cytometry optimization:

  • Optimize cell preparation (live vs. fixed)

  • Test permeabilization protocols for intracellular targets

  • Evaluate fluorophore brightness and stability

  • Optimize compensation for multicolor panels

This cross-platform optimization approach resembles methodologies used in developing versatile antibody applications , where systematic testing across contexts identified optimal conditions for each platform. Maintain detailed records of optimization experiments to build a comprehensive protocol library for the antibody.

How might mug134 Antibody be adapted for emerging single-cell analysis technologies?

Adapting mug134 Antibody for single-cell technologies presents both challenges and opportunities:

• Integration with single-cell transcriptomics:

  • CITE-seq (Cellular Indexing of Transcriptomes and Epitopes by Sequencing):

    • Conjugate mug134 Antibody with oligonucleotide tags

    • Optimize conjugation chemistry to maintain binding capacity

    • Validate single-cell resolution detection alongside RNA profiling

• Mass cytometry (CyTOF) applications:

  • Metal isotope labeling strategies for the antibody

  • Titration for optimal signal-to-noise in multiplexed panels

  • Development of computational frameworks for high-dimensional data analysis

• Single-cell Western blot adaptations:

  • Microfluidic device compatibility testing

  • Sensitivity optimization for detection of low-abundance proteins

  • Protocol adjustments for miniaturized formats

Similar to approaches in developing antibodies for advanced applications , computational modeling of binding characteristics can guide adaptation to new platforms. Consider collaborative approaches with technology developers to optimize integration with proprietary systems.

What potential exists for developing modified versions of mug134 Antibody for specialized applications?

Several modification strategies could enhance mug134 Antibody utility:

• Fragment generation:

  • Fab fragments for reduced steric hindrance

  • F(ab')₂ fragments for applications requiring cross-linking without Fc effects

  • Single-chain variable fragments (scFv) for fusion proteins

• Conjugation opportunities:

  • Enzyme conjugates (HRP, AP) for direct detection

  • Fluorophore conjugates for direct fluorescence applications

  • Nanoparticle conjugation for imaging and therapeutic applications

• Engineered variants:

  • Humanized versions for potential therapeutic applications

  • Affinity-matured variants for increased sensitivity

  • Bispecific formats for co-localization studies

• Expression system modifications:

  • Recombinant expression for batch consistency

  • Glycosylation engineering for modified properties

  • Expression in specialized systems for unique modifications

This approach to antibody engineering resembles methodologies used in developing specialized antibody formats for specific contexts , where structural modifications enhanced functionality for particular applications. When developing modified variants, maintain rigorous validation to ensure that modifications don't compromise specificity.